Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies

Oncotarget

Volumn 7, Issue 35, 2016, Pages 57327-57350

  Fratta, Elisabetta ^a   Montico, Barbara ^a   Rizzo, Aurora ^a   Colizzi, Francesca ^a   Sigalotti, Luca ^a   Dolcetti, Riccardo ^a,b  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

5 aza 2' deoxycytidine; Azacytidine; DNA methylation; Hematological malignancies; Histone modifications

Indexed keywords

ACYLTRANSFERASE INHIBITOR; AZACITIDINE; BENZAMIDE DERIVATIVE; BROMODOMAIN AND EXTRA TERMINAL MOTIF PROTEIN INHIBITOR; BROMODOMAIN PROTEIN; CYCLOPEPTIDE; DECITABINE; DNA METHYLTRANSFERASE; ENZYME; GUADECITABINE; HISTONE ACETYLTRANSFERASE; HISTONE ACYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE METHYLTRANSFERASE INHIBITOR; HYDROXAMIC ACID; ISOCITRATE DEHYDROGENASE INHIBITOR; NUCLEIC ACID BINDING PROTEIN; PROTEIN INHIBITOR; TEN ELEVEN TRANSLOCATION 2; UNCLASSIFIED DRUG; VALPROIC ACID; ANTINEOPLASTIC AGENT; HISTONE;

ARTICLE; DNA HYDROXYMETHYLATION; DNA METHYLATION; ENZYME ACTIVITY; EPIGENETICS; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN TRANSPORT; ACETYLATION; ANALOGS AND DERIVATIVES; CHEMISTRY; CUTANEOUS T CELL LYMPHOMA; FEMALE; GENETIC EPIGENESIS; GENETICS; HEMATOLOGIC DISEASE; MALE; MYELODYSPLASTIC SYNDROME; PROTEIN DOMAIN;

ACETYLATION; ANTINEOPLASTIC AGENTS; AZACITIDINE; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; HEMATOLOGIC NEOPLASMS; HISTONES; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MYELODYSPLASTIC SYNDROMES; PROTEIN DOMAINS;

EID: 84984917796     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10033     Document Type: Article

References (174)

1. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D and Ebert BL. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011; 364:2496-2506.
2. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, Schnittger S, Sanada M, Kon A, Alpermann T, Yoshida K, Roller A, Nadarajah N, Shiraishi Y, Shiozawa Y, Chiba K, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014; 28:241-247.
3. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, Fulton LA, Locke DP, Magrini VJ, Abbott RM, Vickery TL, Reed JS, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009; 361:1058-1066.
4. Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci ND, Heguy A, Cherry A, et al. Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia. The New England journal of medicine. 2012; 366:1079-1089.
5. Illingworth RS and Bird AP. CpG islands-'a rough guide'. FEBS Lett. 2009; 583:1713-1720.
6. Smith ZD and Meissner A. DNA methylation: roles in mammalian development. Nat Rev Genet. 2013; 14:204-220.
7. Kulis M and Esteller M. DNA methylation and cancer. Adv Genet. 2010; 70:27-56.
8. Dahl C, Gronbaek K and Guldberg P. Advances in DNA methylation: 5-hydroxymethylcytosine revisited. Clin Chim Acta. 2011; 412:831-836.
9. Goodell MA and Godley LA. Perspectives and future directions for epigenetics in hematology. Blood. 2013; 121:5131-5137.
10. Broske AM, Vockentanz L, Kharazi S, Huska MR, Mancini E, Scheller M, Kuhl C, Enns A, Prinz M, Jaenisch R, Nerlov C, Leutz A, ndrade-Navarro MA, Jacobsen SE and Rosenbauer F. DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nat Genet. 2009; 41:1207-1215.
11. Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS, Bock C, Vasanthakumar A, Gu H, Xi Y, Liang S, Lu Y, Darlington GJ, Meissner A, Issa JP, Godley LA, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2012; 44:23-31.
12. OstronoffF, Othus M, Ho PA, Kutny M, Geraghty DE, Petersdorf SH, Godwin JE, Willman CL, Radich JP, Appelbaum FR, Stirewalt DL and Meshinchi S. Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report. Leukemia. 2013; 27:238-241.
13. Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, Rockova V, Sanders M, Abbas S, Figueroa ME, Zeilemaker A, Melnick A, Lowenberg B, Valk PJ and Delwel R. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood. 2012; 119:5824-5831.
14. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, Harris CC, Lichti CF, Townsend RR, Fulton RS, Dooling DJ, Koboldt DC, et al. DNMT3A Mutations in Acute Myeloid Leukemia. The New England journal of medicine. 2010; 363:2424-2433.
15. K. Thirukonda V, Raghupathy R and Parekh S. Translational Medicine. 2012.
16. Leone G, Teofili L, Voso MT and Lubbert M. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica. 2002; 87:1324-1341.
17. Rosu-Myles M and WolffL. p15Ink4b: dual function in myelopoiesis and inactivation in myeloid disease. Blood Cells Mol Dis. 2008; 40:406-409.
18. Khan H, Vale C, Bhagat T and Verma A. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes. Semin Hematol. 2013; 50:16-37.
19. Hopfer O, Komor M, Koehler IS, Freitag C, Schulze M, Hoelzer D, Thiel E and Hofmann WK. Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms. Leuk Res. 2009; 33:434-442.
20. Schulz WA, Elo JP, Florl AR, Pennanen S, Santourlidis S, Engers R, Buchardt M, Seifert HH and Visakorpi T. Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer. 2002; 35:58-65.
21. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene. 2002; 21:5400-5413.
22. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Cervantes F, Sanchez J, Garate L, Barrios M, Castillejo JA, Navarro G, Colomer D, Prosper F, Heiniger A and Torres A. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene. 2005; 24:7213-7223.
23. Delhommeau F, Dupont S, Della V, V, James C, Trannoy S, Masse A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lecluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009; 360:2289-2301.
24. Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gäken J, Lea NC, Przychodzen B, Mian SA, Nasser EE, Shooter C, Westwood NB, Strupp C, Gattermann N, Maciejewski JP, Germing U and Mufti GJ. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood. 2010; 116:3923-3932.
25. Butler JS and Dent SY. The role of chromatin modifiers in normal and malignant hematopoiesis. Blood. 2013; 121:3076-3084.
26. Fong CY, Morison J and Dawson MA. Epigenetics in the hematologic malignancies. Haematologica. 2014; 99:1772-1783.
27. Rothbart SB and Strahl BD. Interpreting the language of histone and DNA modifications. Biochim Biophys Acta. 2014; 1839:627-643.
28. MarzluffWF and Duronio RJ. Histone mRNA expression: multiple levels of cell cycle regulation and important developmental consequences. Curr Opin Cell Biol. 2002; 14:692-699.
29. Talbert PB and HenikoffS. Histone variants-ancient wrap artists of the epigenome. Nat Rev Mol Cell Biol. 2010; 11:264-275.
30. MarzluffWF, Wagner EJ and Duronio RJ. Metabolism and regulation of canonical histone mRNAs: life without a poly(A) tail. Nat Rev Genet. 2008; 9:843-854.
31. Weber CM, Ramachandran S and HenikoffS. Nucleosomes are context-specific, H2A.Z-modulated barriers to RNA polymerase. Mol Cell. 2014; 53:819-830.
32. Conerly ML, Teves SS, Diolaiti D, Ulrich M, Eisenman RN and HenikoffS. Changes in H2A.Z occupancy and DNA methylation during B-cell lymphomagenesis. Genome Res. 2010; 20:1383-1390.
33. Je EM, Yoo NJ, Kim YJ, Kim MS and Lee SH. Somatic mutation of H3F3A, a chromatin remodeling gene, is rare in acute leukemias and non-Hodgkin lymphoma. European Journal of Haematology. 2013; 90:169-170.
34. Vardabasso C, Hasson D, Ratnakumar K, Chung CY, Duarte LF and Bernstein E. Histone variants: emerging players in cancer biology. Cell Mol Life Sci. 2014; 71:379-404.
35. Novik KL, Spinelli JJ, Macarthur AC, Shumansky K, Sipahimalani P, Leach S, Lai A, Connors JM, Gascoyne RD, Gallagher RP and Brooks-Wilson AR. Genetic variation in H2AFX contributes to risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2007; 16:1098-1106.
36. Morgan MA and Shilatifard A. Chromatin signatures of cancer. Genes Dev. 2015; 29:238-249.
37. Morin RD, Mungall K, Pleasance E, Mungall AJ, Goya R, HuffRD, Scott DW, Ding J, Roth A, Chiu R, Corbett RD, Chan FC, Mendez-Lago M, Trinh DL, Bolger-Munro M, Taylor G, et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood. 2013; 122:1256-1265.
38. Li H, Kaminski MS, Li Y, Yildiz M, Ouillette P, Jones S, Fox H, Jacobi K, Saiya-Cork K, Bixby D, Lebovic D, Roulston D, Shedden K, Sabel M, Marentette L, Cimmino V, et al. Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Blood. 2014; 123:1487-1498.
39. Greer EL and Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012; 13:343-357.
40. Muller J, Hart CM, Francis NJ, Vargas ML, Sengupta A, Wild B, Miller EL, O'Connor MB, Kingston RE and Simon JA. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell. 2002; 111:197-208.
41. Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SN, Wang L, Ezponda T, Martinez-Garcia E, Zhang H, Zheng Y, Verma SK, McCabe MT, Ott HM, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013; 23:677-692.
42. Velichutina I, Shaknovich R, Geng H, Johnson NA, Gascoyne RD, Melnick AM and Elemento O. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood. 2010; 116:5247-5255.
43. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, Yap D, Humphries RK, Griffith OL, Shah S, Zhu H, Kimbara M, et al. Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin. Nature genetics. 2010; 42:181-185.
44. Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A, Morin RD, Mungall AJ, Meissner B, Boyle M, Marquez VE, Marra MA, Gascoyne RD, Humphries RK, Arrowsmith CH, Morin GB, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood. 2011; 117:2451-2459.
45. Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM and Copeland RA. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A. 2010; 107:20980-20985.
46. Popovic R, Shah MY and Licht JD. Epigenetic therapy of hematological malignancies: where are we now? Therapeutic Advances in Hematology. 2013; 4:81-91.
47. Abdel-Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A, Beran M, Gilliland DG, Levine RL and Tefferi A. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia. 2011; 25:1200-1202.
48. Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tonnissen ER, van der HA, Scheele TN, Vandenberghe P, de WT, van der Reijden BA and Jansen JH. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010; 42:665-667.
49. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, Waghorn K, Zoi K, Ross FM, Reiter A, Hochhaus A, Drexler HG, Duncombe A, Cervantes F, Oscier D, Boultwood J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010; 42:722-726.
50. Jaju RJ, Fidler C, Haas OA, Strickson AJ, Watkins F, Clark K, Cross NC, Cheng JF, Aplan PD, Kearney L, Boultwood J and Wainscoat JS. A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia. Blood. 2001; 98:1264-1267.
51. Wang GG, Cai L, Pasillas MP and Kamps MP. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol. 2007; 9:804-812.
52. Keats JJ, Reiman T, Belch AR and Pilarski LM. Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma. Leuk Lymphoma. 2006; 47:2289-2300.
53. Huang Z, Wu H, Chuai S, Xu F, Yan F, Englund N, Wang Z, Zhang H, Fang M, Wang Y, Gu J, Zhang M, Yang T, Zhao K, Yu Y, Dai J, et al. NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma. Cancer Res. 2013; 73:6277-6288.
54. Guenther MG, Jenner RG, Chevalier B, Nakamura T, Croce CM, Canaani E and Young RA. Global and Hox-specific roles for the MLL1 methyltransferase. Proc Natl Acad Sci U S A. 2005; 102:8603-8608.
55. Slany RK. The molecular biology of mixed lineage leukemia. Haematologica. 2009; 94:984-993.
56. Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J, Ben Abdelali R, Macintyre E, De Braekeleer E, De Braekeleer M, Delabesse E, de Oliveira MP, Cave H, Clappier E, van Dongen JJM, Balgobind BV, et al. New insights to the MLL recombinome of acute leukemias. Leukemia. 2009; 23:1490-1499.
57. Dou Y and Hess JL. Mechanisms of transcriptional regulation by MLL and its disruption in acute leukemia. Int J Hematol. 2008; 87:10-18.
58. Krivtsov AV and Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007; 7:823-833.
59. Deshpande AJ, Chen L, Fazio M, Sinha AU, Bernt KM, Banka D, Dias S, Chang J, Olhava EJ, Daigle SR, Richon VM, Pollock RM and Armstrong SA. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood. 2013; 121:2533-2541.
60. Cheung N, Chan LC, Thompson A, Cleary ML and So CW. Protein arginine-methyltransferase-dependent oncogenesis. Nat Cell Biol. 2007; 9:1208-1215.
61. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, Cruz-Gordillo P, Knoechel B, Asmann YW, Slager SL, Novak AJ, Dogan A, Ansell SM, Link BK, Zou L, Gould J, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012; 109:3879-3884.
62. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, Kasper LH, Lerach S, Tang H, Ma J, Rossi D, Chadburn A, Murty VV, Mullighan CG, Gaidano G, Rabadan R, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011; 471:189-195.
63. Green MR, Kihira S, Liu CL, Nair RV, Salari R, Gentles AJ, Irish J, Stehr H, Vicente-Duenas C, Romero-Camarero I, Sanchez-Garcia I, Plevritis SK, Arber DA, Batzoglou S, Levy R and Alizadeh AA. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci U S A. 2015; 112:E1116-E1125.
64. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers C, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110:1398-1403.
65. Lakshmikuttyamma A, Takahashi N, Pastural E, Torlakovic E, Amin HM, Garcia-Manero G, Voralia M, Czader M, Decoteau JF and Geyer CR. RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression. J Hematol Oncol. 2009; 2:28.
66. Steele-Perkins G, Fang W, Yang XH, Van GM, Carling T, Gu J, Buyse IM, Fletcher JA, Liu J, Bronson R, Chadwick RB, de la CA, Zhang X, Speleman F and Huang S. Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily. Genes Dev. 2001; 15:2250-2262.
67. Fears S, Mathieu C, Zeleznik-Le N, Huang S, Rowley JD and Nucifora G. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc Natl Acad Sci U S A. 1996; 93:1642-1647.
68. Liu L, Shao G, Steele-Perkins G and Huang S. The retinoblastoma interacting zinc finger gene RIZ produces a PR domain-lacking product through an internal promoter. J Biol Chem. 1997; 272:2984-2991.
69. Brooks DJ, Woodward S, Thompson FH, Dos SB, Russell M, Yang JM, Guan XY, Trent J, Alberts DS and Taetle R. Expression of the zinc finger gene EVI-1 in ovarian and other cancers. Br J Cancer. 1996; 74:1518-1525.
70. GraffJ and Tsai LH. Histone acetylation: molecular mnemonics on the chromatin. Nat Rev Neurosci. 2013; 14:97-111.
71. Perez-Campo FM, Borrow J, KouskoffV and Lacaud G. The histone acetyl transferase activity of monocytic leukemia zinc finger is critical for the proliferation of hematopoietic precursors. Blood. 2009; 113:4866-4874.
72. Collins HM, Kindle KB, Matsuda S, Ryan C, Troke PJ, Kalkhoven E and Heery DM. MOZ-TIF2 alters cofactor recruitment and histone modification at the RARbeta2 promoter: differential effects of MOZ fusion proteins on CBP-and MOZ-dependent activators. J Biol Chem. 2006; 281:17124-17133.
73. Deguchi K, Ayton PM, Carapeti M, Kutok JL, Snyder CS, Williams IR, Cross NC, Glass CK, Cleary ML and Gilliland DG. MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. Cancer Cell. 2003; 3:259-271.
74. Kindle KB, Troke PJ, Collins HM, Matsuda S, Bossi D, Bellodi C, Kalkhoven E, Salomoni P, Pelicci PG, Minucci S and Heery DM. MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function. Mol Cell Biol. 2005; 25:988-1002.
75. Rebel VI, Kung AL, Tanner EA, Yang H, Bronson RT and Livingston DM. Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc Natl Acad Sci U S A. 2002; 99:14789-14794.
76. Huang W-C, Ju T-K, Hung M-C and Chen C-C. Phosphorylation of CBP by IKK Promotes Cell Growth by Switching the Binding Preference of CBP from p53 to NFB. Molecular Cell. 2007; 26:75-87.
77. Chan EM, Chan RJ, Comer EM, Goulet Iii RJ, Crean CD, Brown ZD, Fruehwald AM, Yang Z, Boswell HS, Nakshatri H and Gabig TG. MOZ and MOZ-CBP cooperate with NF-B to activate transcription from NF-B-dependent promoters. Experimental Hematology. 2007; 35:1782-1792.
78. Cohen I, Poreba E, Kamieniarz K and Schneider R. Histone modifiers in cancer: friends or foes? Genes Cancer. 2011; 2:631-647. doi: 10.1177/1947601911417176.
79. Giannini G, Cabri W, Fattorusso C and Rodriquez M. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Med Chem. 2012; 4:1439-1460.
80. Martinez-Redondo P and Vaquero A. The diversity of histone versus nonhistone sirtuin substrates. Genes Cancer. 2013; 4:148-163. doi: 10.1177/1947601913483767.
81. Bolden JE, Peart MJ and Johnstone RW. Anticancer activities of histone deacetylase inhibitors 157 Nat Rev Drug Discov. 2006; 5:769-784.
82. Ropero S and Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007; 1:19-25.
83. Minucci S, Nervi C, Lo CF and Pelicci PG. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene. 2001; 20:3110-3115.
84. Zelent A, Guidez F, Melnick A, Waxman S and Licht JD. Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene. 2001; 20:7186-7203.
85. Cress WD and Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol. 2000; 184:1-16.
86. Subramanyam D, Belair CD, Barry-Holson KQ, Lin H, Kogan SC, Passegue E and Blelloch R. PML-RAR(alpha) and Dnmt3a1 cooperate in vivo to promote acute promyelocytic leukemia. Cancer Res. 2010; 70:8792-8801.
87. Minucci S and Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006; 6:38-51.
88. Uribesalgo I and Di CL. Dynamics of epigenetic modifications in leukemia. Brief Funct Genomics. 2011; 10:18-29.
89. de TH and Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer. 2010; 10:775-783.
90. Reikvam H, Hatfield KJ, Kittang AO, Hovland R and Bruserud O. Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications. J Biomed Biotechnol. 2011; 2011:104631.
91. Huang B, Yang XD, Zhou MM, Ozato K and Chen LF. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol Cell Biol. 2009; 29:1375-1387.
92. Lamonica JM, Deng W, Kadauke S, Campbell AE, Gamsjaeger R, Wang H, Cheng Y, Billin AN, Hardison RC, Mackay JP and Blobel GA. Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes. Proc Natl Acad Sci U S A. 2011; 108:E159-E168.
93. Filippakopoulos P and Knapp S. The bromodomain interaction module. FEBS Lett. 2012; 586:2692-2704.
94. Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D, Felletar I, Volkmer R, Muller S, Pawson T, Gingras AC, Arrowsmith CH and Knapp S. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012; 149:214-231.
95. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, BantscheffM, Chan WI, Robson SC, Chung CW, Hopf C, Savitski MM, Huthmacher C, Gudgin E, Lugo D, Beinke S, Chapman TD, Roberts EJ, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLLfusion leukaemia. Nature. 2011; 478:529-533.
96. Anand P, Brown JD, Lin CY, Qi J, Zhang R, Artero PC, Alaiti MA, Bullard J, Alazem K, Margulies KB, Cappola TP, Lemieux M, Plutzky J, Bradner JE and Haldar SM. BET bromodomains mediate transcriptional pause release in heart failure. Cell. 2013; 154:569-582.
97. Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI and Young RA. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013; 153:320-334.
98. Zhang W, Prakash C, Sum C, Gong Y, Li Y, Kwok JJ, Thiessen N, Pettersson S, Jones SJ, Knapp S, Yang H and Chin KC. Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012; 287:43137-43155.
99. Garcia JS, Jain N and Godley LA. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes. Onco Targets Ther. 2010; 3:1-13.
100. Amatori S, Bagaloni I, Donati B and Fanelli M. DNA demethylating antineoplastic strategies: a comparative point of view. Genes Cancer. 2010; 1:197-209. doi: 10.1177/1947601910365081.
101. Estey EH. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Leukemia. 2013; 27:1803-1812.
102. Joeckel TE and Lubbert M. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update. Semin Hematol. 2012; 49:330-341.
103. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J and Kantarjian HM. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004; 103:1635-1640.
104. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL and Larson RA. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006; 24:3895-3903.
105. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10:223-232.
106. Font P. Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia. Adv Ther. 2011; 28 Suppl 3:1-9.
107. Dombret H and Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2015.
108. Malik P and Cashen AF. Decitabine in the treatment of acute myeloid leukemia in elderly patients. Cancer Manag Res. 2014; 6:53-61.
109. Voso MT, Lo-Coco F and Fianchi L. Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia. Curr Opin Oncol. 2015; 27:532-539.
110. Griffiths EA and Gore SD. Epigenetic therapies in MDS and AML. Adv Exp Med Biol. 2013; 754:253-283.
111. Ruter B, Wijermans PW and Lubbert M. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer. 2006; 106:1744-1750.
112. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, et al. Results of a randomized study of 3 schedules of lowdose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. 88. Blood. 2007; 109:52-57.
113. Cashen AF, Schiller GJ, O'Donnell MR and DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010; 28:556-561.
114. Chuang JC, Warner SL, Vollmer D, Vankayalapati H, Redkar S, Bearss DJ, Qiu X, Yoo CB and Jones PA. S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010; 9:1443-1450.
115. Coral S, Parisi G, Nicolay HJ, Colizzi F, Danielli R, Fratta E, Covre A, Taverna P, Sigalotti L and Maio M. Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide. Cancer Immunol Immunother. 2013; 62:605-614.
116. Foulks JM, Parnell KM, Nix RN, Chau S, Swierczek K, Saunders M, Wright K, Hendrickson TF, Ho KK, McCullar MV and Kanner SB. Epigenetic drug discovery: targeting DNA methyltransferases. J Biomol Screen. 2012; 17:2-17.
117. Lavelle D, Saunthararajah Y, Vaitkus K, Singh M, Banzon V, Phiasivongsva P, Redkar S, Kanekal S, Bearss D, Shi C, Inloes R and DeSimone J. S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis). J Transl Med. 2010; 8:92.
118. Montalban-Bravo G and Garcia-Manero G. Novel drugs for older patients with acute myeloid leukemia. Leukemia. 2015; 29:760-769.
119. Blum KA, Liu Z, Lucas DM, Chen P, Xie Z, Baiocchi R, Benson DM, Devine SM, Jones J, Andritsos L, Flynn J, Plass C, Marcucci G, Chan KK, Grever MR and Byrd JC. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: doselimiting myelosuppression without evidence of DNA hypomethylation. Br J Haematol. 2010; 150:189-195.
120. Stathis A, Hotte SJ, Chen EX, Hirte HW, Oza AM, Moretto P, Webster S, Laughlin A, Stayner LA, McGill S, Wang L, Zhang WJ, Espinoza-Delgado I, Holleran JL, Egorin MJ and Siu LL. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clin Cancer Res. 2011; 17:1582-1590.
121. Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S and Wistuba II. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res. 2009; 15:3881-3888.
122. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, Straley K, Kernytsky A, Liu W, Gliser C, Yang H, Gross S, Artin E, Saada V, Mylonas E, Quivoron C, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013; 340:622-626.
123. Stein EM. Molecular Pathways: IDH2 Mutations-Co-opting Cellular Metabolism for Malignant Transformation. Clin Cancer Res. 2016; 22:16-19.
124. Fredly H, Gjertsen BT and Bruserud O. Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clin Epigenetics. 2013; 5:12.
125. Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R, Germing U and Gattermann N. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood. 2004; 104:1266-1269.
126. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'Brien S, Estey E, et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006; 108:3271-3279.
127. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM and Garcia-Manero G. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007; 110:2302-2308.
128. Raffoux E, Cras A, Recher C, Boelle PY, de LA, Turlure P, Marolleau JP, Reman O, Gardin C, Victor M, Maury S, Rousselot P, Malfuson JV, Maarek O, Daniel MT, Fenaux P, et al. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget. 2010; 1:34-42. doi: 10.18632/oncotarget.106
129. Craddock C, Quek L, Goardon N, Freeman S, Siddique S, Raghavan M, Aztberger A, Schuh A, Grimwade D, Ivey A, Virgo P, Hills R, McSkeane T, Arrazi J, Knapper S, Brookes C, et al. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia. 2013; 27:1028-1036.
130. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM and Frankel SR. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007; 109:31-39.
131. Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V, Matsuoka D, Pulone B, Rotter AJ, Espinoza-Delgado I, Nademanee A, Forman SJ, Gandara D and Newman E. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2011; 29:1198-1203.
132. Silva G, Cardoso BA, Belo H and Almeida AM. Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms. PLoS One. 2013; 8:e53766.
133. Zhang C, Richon V, Ni X, Talpur R and Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol. 2005; 125:1045-1052.
134. Zhao WL, Wang L, Liu YH, Yan JS, Leboeuf C, Liu YY, Wu WL, Janin A, Chen Z and Chen SJ. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis. Exp Hematol. 2007; 35:1801-1811.
135. Chen R, Frankel P, Popplewell L, Siddiqi T, Ruel N, Rotter A, Thomas SH, Mott M, Nathwani N, Htut M, Nademanee A, Forman SJ and Kirschbaum M. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. Haematologica. 2015; 100:357-362.
136. Duvic M and Dimopoulos M. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies. Cancer Treatment Reviews. 2016; 43:58-66.
137. Laubach JP, Moreau P, San-Miguel JF and Richardson PG. Panobinostat for the Treatment of Multiple Myeloma. Clin Cancer Res. 2015; 21:4767-4773.
138. Scuto A, Kirschbaum M, Kowolik C, Kretzner L, Juhasz A, Atadja P, Pullarkat V, Bhatia R, Forman S, Yen Y and Jove R. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph-acute lymphoblastic leukemia cells. Blood. 2008; 111:5093-5100.
139. Rosato R, Hock S, Dent P, Dai Y and Grant S. LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK-and XIAP-dependent mechanism. Leuk Res. 2012; 36:491-498.
140. Xie C, Drenberg C, Edwards H, Caldwell JT, Chen W, Inaba H, Xu X, Buck SA, Taub JW, Baker SD and Ge Y. Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51. PLoS One. 2013; 8:e79106.
141. Tan P, Wei A, Mithraprabhu S, Cummings N, Liu HB, Perugini M, Reed K, Avery S, Patil S, Walker P, Mollee P, Grigg A, D'Andrea R, Dear A and Spencer A. Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer J. 2014; 4:e170.
142. O'Connor OA, Horwitz S, Masszi T, Van HA, Brown P, Doorduijn J, Hess G, Jurczak W, Knoblauch P, Chawla S, Bhat G, Choi MR, Walewski J, Savage K, Foss F, Allen LF, et al. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. J Clin Oncol. 2015; 33:2492-2499.
143. Bodiford A, Bodge M, Talbott MS and Reddy NM. Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma. Onco Targets Ther. 2014; 7:1971-1977.
144. Sawas A, Radeski D and O'Connor OA. Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review. Ther Adv Hematol. 2015; 6:202-208.
145. Kirschbaum MH, Foon KA, Frankel P, Ruel C, Pulone B, Tuscano JM and Newman EM. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma. 2014; 55:2301-2304.
146. Cashen A, Juckett M, Jumonville A, Litzow M, Flynn PJ, Eckardt J, LaPlant B, Laumann K, Erlichman C and DiPersio J. Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS). Ann Hematol. 2012; 91:33-38.
147. Kalac M, Scotto L, Marchi E, Amengual J, Seshan VE, Bhagat G, Ulahannan N, Leshchenko VV, Temkin AM, Parekh S, Tycko B and O'Connor OA. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood. 2011; 118:5506-5516.
148. Bose P and Grant S. Orphan drug designation for pracinostat, volasertib and alvocidib in AML. Leuk Res. 2014; 38:862-865.
149. Yoo CB and Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006; 5:37-50.
150. Prebet T, Sun Z, Figueroa ME, Ketterling R, Melnick A, Greenberg PL, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, Litzow M, Gabrilove J, Erba HP, Gore SD, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. J Clin Oncol. 2014; 32:1242-1248.
151. Jona A, Khaskhely N, Buglio D, Shafer JA, Derenzini E, Bollard CM, Medeiros LJ, Illes A, Ji Y and Younes A. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Exp Hematol. 2011; 39:1007-1017.
152. Frys S, Simons Z, Hu Q, Barth MJ, Gu JJ, Mavis C, Skitzki J, Song L, Czuczman MS and Hernandez-Ilizaliturri FJ. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents. Br J Haematol. 2015; 169:506-519.
153. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009; 27:5410-5417.
154. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, et al. Results from a pivotal, openlabel, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012; 30:631-636.
155. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan IS, Shustov A, Nielsen T, Nichols J, Wolfson J, Balser B, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014; 7:11.
156. Klimek VM, Fircanis S, Maslak P, Guernah I, Baum M, Wu N, Panageas K, Wright JJ, PandolfiPP and Nimer SD. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res. 2008; 14:826-832.
157. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Sklenar AR, Davis ME, Lucas DM, Fischer B, Shank R, Tejaswi SL, Binkley P, Wright J, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood. 2005; 105:959-967.
158. Valdez BC, Brammer JE, Li Y, Murray D, Liu Y, Hosing C, Nieto Y, Champlin RE and Andersson BS. Romidepsin targets multiple survival signaling pathways in malignant T cells. Blood Cancer J. 2015; 5:e357.
159. Ghoneum M and Gollapudi S. Synergistic apoptotic effect of arabinoxylan rice bran (MGN-3/Biobran) and curcumin (turmeric) on human multiple myeloma cell line U266 in vitro. Neoplasma. 2011; 58:118-123.
160. Nebbioso A, Carafa V, Benedetti R and Altucci L. Trials with 'epigenetic' drugs: an update. Mol Oncol. 2012; 6:657-682.
161. Aggarwal BB, Deb L and Prasad S. Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses. Molecules. 2015; 20:185-205.
162. Eliseeva ED, Valkov V, Jung M and Jung MO. Characterization of novel inhibitors of histone acetyltransferases. Mol Cancer Ther. 2007; 6:2391-2398.
163. Hlubek F, Lohberg C, Meiler J, Jung A, Kirchner T and Brabletz T. Tip60 is a cell-type-specific transcriptional regulator. J Biochem. 2001; 129:635-641.
164. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, Ustun C, Rao R, Fernandez P, Chen J, Balusu R, Koul S, Atadja P, Marquez VE and Bhalla KN. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood. 2009; 114:2733-2743.
165. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della PA, III, Diaz E, LaFrance LV, Mellinger M, Duquenne C, Tian X, Kruger RG, McHugh CF, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012; 492:108-112.
166. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, Sacks JD, Raimondi A, Majer CR, Song J, Scott MP, Jin L, Smith JJ, Olhava EJ, Chesworth R, Moyer MP, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. 2012; 8:890-896.
167. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, Johnston LD, Scott MP, Smith JJ, Xiao Y, Jin L, Kuntz KW, Chesworth R, Moyer MP, Bernt KM, Tseng JC, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011; 20:53-65.
168. Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA, Allain CJ, Klaus CR, Raimondi A, Scott MP, Waters NJ, Chesworth R, Moyer MP, Copeland RA, Richon VM and Pollock RM. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013; 122:1017-1025.
169. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, Chandwani R, Marazzi I, Wilson P, Coste H, White J, Kirilovsky J, Rice CM, Lora JM, Prinjha RK, Lee K, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010; 468:1119-1123.
170. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, West N, et al. Selective inhibition of BET bromodomains. Nature. 2010; 468:1067-1073.
171. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011; 146:904-917.
172. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, Bergeron L and Sims RJ, III. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A. 2011; 108:16669-16674.
173. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011; 478:524-528.
174. Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, Rodig SJ, Kung AL, Bradner JE and Weinstock DM. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012; 120:2843-2852.